医药市场规模、份额和成长分析（按产品、经济、适应症、分销管道和地区）- 2025-2032 年产业预测

预计 2023 年全球医药市场规模将达到 1.8 兆美元，并从 2024 年的 1.89 兆美元成长到 2032 年的 2.84 兆美元，预测期内（2025-2032 年）的复合年增长率为 5.2%。

由于非传染性疾病盛行率上升、预期寿命增加、人均收入增加和政府医疗支出增加等几个关键因素，全球医药市场预计将大幅成长。人口老化推动了对旨在改善患者治疗效果的先进创新医疗产品的需求增加。新产品的推出正在蓬勃发展，预计未来五年将有约 300 种新药上市，预计专科药、小众药和孤儿药类别将出现尤其显着的增长，预计支出将达到 1,960 亿美元。然而，该市场的特点是现有企业之间的竞争非常激烈，并且有越来越多的新参与企业寻求利用尚未开发的商业机会，从而创造出一个充满活力且不断发展的市场格局。

目录

介绍

• 调查目的
• 研究范围
• 定义

调查方法

• 资讯采购
• 次要和资料资料
• 市场规模预测
• 市场假设与限制

执行摘要

• 全球市场展望
• 供需趋势分析
• 细分市场机会分析

市场动态及展望

• 市场概况
• 市场规模
• 市场动态
  • 驱动因素和机会
  • 限制与挑战
• 波特的分析

主要市场考察

• 关键成功因素
• 竞争程度
• 主要投资机会
• 市场生态系统
• 市场吸引力指数（2024 年）
• PESTEL 分析
• 总体经济指标
• 价值链分析
• 定价分析

医药市场规模（依产品及复合年增长率） (2025-2032)

• 市场概况
• 药品
  • 取得专利的处方药
  • 非专利处方药
  • 非处方药
• 其他医疗业
  • 医疗设备
  • 临床诊断
  • 其他的

依经济和复合年增长率分類的医药市场规模（2025-2032）

• 市场概况
• 第 1层级
• 第 2层级
• 第 3层级

医药市场规模（按适应症和复合年增长率） (2025-2032)

• 市场概况
• 文明病
• 癌症与自体免疫疾病
• 感染疾病
• 其他的

依分销管道分類的医药市场规模及复合年增长率（2025-2032 年）

• 市场概况
• 医院
• 网路商店
• 零售药局
• 其他的

各地区医药市场规模及复合年增长率（2025-2032）

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲国家地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 其他亚太地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲国家
• 中东和非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东和非洲地区

竞争资讯

• 前 5 家公司对比
• 主要企业市场定位（2024年）
• 主要市场参与者所采用的策略
• 近期市场趋势
• 公司市场占有率分析（2024 年）
• 主要企业简介
  • 公司简介
  • 产品系列分析
  • 按细分市场分析市场份额
  • 收益与前一年同期比较（2022-2024 年）

主要企业简介

• Pfizer Inc.（USA）
• Novartis AG（Switzerland）
• Roche Holding AG（Switzerland）
• Sanofi SA（France）
• AstraZeneca PLC（UK）
• GlaxoSmithKline plc（UK）
• Johnson & Johnson（USA）
• Abbott Laboratories（USA）
• Sun Pharmaceutical Industries Ltd.（India）
• Cipla Ltd.（India）
• Dr. Reddy's Laboratories Ltd.（India）
• Lupin Ltd.（India）
• Teva Pharmaceutical Industries Ltd.（Israel）
• Valeant Pharmaceuticals International（Canada）
• Merck & Co., Inc.（USA）
• Bristol Myers Squibb（USA）
• Takeda Pharmaceutical Company Limited（Japan）
• Sinopharm（China）
• Shanghai Fosun Pharmaceutical（Group）Co., Ltd（China）
• EMS SA（Brazil）

结论和建议

Global Pharmerging Market size was valued at USD 1.8 trillion in 2023 and is poised to grow from USD 1.89 trillion in 2024 to USD 2.84 trillion by 2032, growing at a CAGR of 5.2% during the forecast period (2025-2032).

The global pharmerging market is poised for significant growth driven by several pivotal factors including the increasing prevalence of non-communicable diseases, rising life expectancy, heightened per capita income, and escalated government healthcare spending. The aging population further intensifies the demand for advanced and innovative medical products aimed at improved patient outcomes. Proliferation in new product launches, with approximately 300 new drugs expected in the next five years-especially in specialty, niche, and orphan categories-signals a noteworthy expansion, projected to generate USD 196 billion in spending. However, the market is marked by fierce competition among established players and a steady influx of new entrants targeting untapped opportunities, shaping a dynamic and evolving landscape ahead.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Pharmerging market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Pharmerging Market Segmental Analysis

Global Pharmerging Market is segmented by Product, Economy, Indication, Distribution Channel and region. Based on Product, the market is segmented into Pharmaceutical and Other Healthcare Verticals. Based on Economy, the market is segmented into Tier-1, Tier-2 and Tier-3. Based on Indication, the market is segmented into Lifestyle Diseases, Cancer & Autoimmune Diseases, Infectious Diseases and Others. Based on Distribution Channel, the market is segmented into Hospitals, online stores, retail pharmacies and others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Pharmerging Market

The global pharmerging market is propelled by several key factors, including the high incidence of chronic diseases, increased awareness among consumers regarding early disease detection and treatment options, and ongoing advancements in research and development. Additionally, rising life expectancy plays a significant role in this market's growth. Government initiatives in emerging economies like India, China, and Indonesia further enhance consumer awareness about pharmaceutical innovations. The proliferation of insurance companies offering diverse coverage to reduce the financial burden of pharmerging treatments also boosts demand for pharmaceuticals worldwide. A pertinent example is Hexvix, which has been added to the 2022 Lecheng Global Specialty Drug Insurance Drug List for bladder cancer diagnosis.

Restraints in the Global Pharmerging Market

The growth of the global Pharmerging market may face significant challenges due to concerns related to intellectual property protection and socio-political factors affecting cross-border transactions. Additionally, stringent price controls could lead to value erosion, further restraining market expansion in the upcoming years. Moreover, the stringent approval processes imposed by government regulatory bodies for the introduction and use of pharmaceuticals can hinder market growth throughout the forecast period. These factors collectively pose substantial risks that could limit the potential development and profitability of the Pharmerging market in a fluctuating global landscape.

Market Trends of the Global Pharmerging Market

The global pharmerging market is witnessing robust growth driven by heightened R&D activities in biotechnology, immunology, and oncology sectors, which are reshaping healthcare paradigms. Major pharmaceutical companies are prioritizing the development of innovative technologies that enhance user convenience and improve patient outcomes. Additionally, the rapid increase in global population, coupled with rising disease prevalence, is further propelling demand for advanced healthcare solutions. This synergy of innovation and necessity is fostering an environment ripe for investment and expansion in emerging markets, making them pivotal players in the global pharmaceutical landscape as they seek to address both local and global health challenges.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Pharmerging Market Size by Product & CAGR (2025-2032)

• Market Overview
• Pharmaceutical
  • Patented Prescription Drugs
  • Generic Prescription Drugs
  • OTC Drugs
• Other Healthcare Verticals
  • Medical Device
  • Clinical Diagnostics
  • Others

Global Pharmerging Market Size by Economy & CAGR (2025-2032)

• Market Overview
• Tier-1
• Tier-2
• Tier-3

Global Pharmerging Market Size by Indication & CAGR (2025-2032)

• Market Overview
• Lifestyle Diseases
• Cancer & Autoimmune Diseases
• Infectious Diseases
• Others

Global Pharmerging Market Size by Distribution Channel & CAGR (2025-2032)

• Market Overview
• Hospitals
• online stores
• retail pharmacies
• others

Global Pharmerging Market Size & CAGR (2025-2032)

• North America (Product, Economy, Indication, Distribution Channel)
  • US
  • Canada
• Europe (Product, Economy, Indication, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Product, Economy, Indication, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Product, Economy, Indication, Distribution Channel)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Product, Economy, Indication, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Pfizer Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Roche Holding AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi S.A. (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca PLC (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline plc (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Abbott Laboratories (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sun Pharmaceutical Industries Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cipla Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Dr. Reddy's Laboratories Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Lupin Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd. (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Valeant Pharmaceuticals International (Canada)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol Myers Squibb (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Limited (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sinopharm (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Shanghai Fosun Pharmaceutical (Group) Co., Ltd (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• EMS S.A. (Brazil)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations